FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Novo Nordisk Asks Liraglutide Drug ANDA Restrictions

[ Price : $8.95]

Novo Nordisk asks FDA not to approve any ANDA for a drug referencing any of its liragltide-containing drugs and put restrictions o...

Pfizer Sees Potential Guidance Conflicts

[ Price : $8.95]

Pfizer tells FDA that an agency draft guidance on CMC postapproval manufacturing changes for specified biological products may con...

FDA Accepts Allergan NDA for Uterine Fibroids

[ Price : $8.95]

FDA accepts an Allergan NDA for ulipristal acetate, an investigational drug for treating abnormal uterine bleeding in women with u...

FDA Rejects Mylans BLA for Neulasta Biosimilar

[ Price : $8.95]

FDA issues a complete response letter for Mylans BLA for MYL-1401H, a proposed biosimilar of Amgens Neulasta (pegfilgrastim).

Latest FDA Warning Letters

[ Price : $8.95]

FDA releases its latest batch of Warning Letters that includes Diasol, Euro Diagnostica, Option Care, and Laveeza Bhatti.

FDA Priority Review for Ultragenyx/Kyowa BLA

[ Price : $8.95]

FDA accepts for priority review an Ultragenyx Pharmaceutical and Kyowa BLA for burosumab to treat pediatric and adult patients wit...

Reviewers Ask Tough Luxturna Questions

[ Price : $8.95]

FDA medical reviewers ask members of the Cellular, Tissue, and Gene Therapies Advisory Committee for their opinion on difficult qu...

Healthcare Technology Safety Bill Introduced

[ Price : $8.95]

Reps. Brooks and Trott introduce a bill creating a public-private partnership to protect Americans sensitive healthcare informatio...

FDA Priority Review for Boehringer Gilotrif sNDA

[ Price : $8.95]

In its fourth major decision since May for drug products aimed at non-small lung cancer (NSCLC), FDA accepts for priority review a...

Cardio Device Status Indicators Not 510(k) Exempt

[ Price : $8.95]

Federal Register correction: FDA corrects a final order entitled Medical Devices; Cardiovascular Devices; Classification of the Ad...